ncology Services at ural Hospitals

Michael Azzolin PharmD | MBA | CEO

Patrick Brown, AVP






Reasons to consider oncology services in rural Hospitals

Collectively, patients and their families reduced their travel to medical appointments by 65,456 miles and 1,757 hours, translating to \$65,791 in costs savings.

https://www.accc-cancer.org/docs/Documents/oncology-issues/articles/so19/so19-virtual-infusion-services

- Increased adherence
 - Improved outcomes
- Patient convenience
- Decreased overall costs
- Additional hospital revenue

Geographic Relevance



PharmD on Demand

Viability of Oncology Infusion Centers in Rural Communities


Encouraging Drivers

- Reimbursement for SCH and CAH hospital types
 - -ASP = 6% vs. ASP 22% for Medicare patients
 - -340B Purchasing Power
 - Orphan drug status
 - GPO exclusions
- Patients

Barriers and Challenges

- Startup and ongoing Costs
- Reimbursement Challenges
- White Bagging





Medicaid Transaction Specific Reimbursements


HCPCS

→ OR → Description: KEYTRUDA IN... (1) →

	Serial Number ⊘	HCPCS	AHAWAA AMAT AR V	Jnit (TY	
1.	19J9271	J9271	\$5,391.47	200	
2.	20J9271	J9271	\$5,391.47	200	
3.	21J9271	J9271	\$5,391.47	200	
4.	22J9271	J9271	\$5,391.47	200	
5.	23J9271	J9271	\$5,390.75	200	
6.	24J9271	J9271	\$5,390.75	200	
7.	25J9271	J9271	\$5,390.75	200	
8.	26J9271	J9271	\$5,390.75	200	
9.	27J9271	J9271	\$5,390.65	200	
10.	28J9271	J9271	\$5,344.62	200	
11.	29J9271	J9271	\$5,344.6	200	
12.	30J9271	J9271	\$5,341.69	200	
13.	31J9271	J9271	\$5,340.94	200	
		Grand total	\$166,056.69 20,3	300	
			1 - 100 / 121 <	1 - 100 / 121 🔇 🗦	

Analysis of all JCODE reimbursement allowed amounts less the 340B or WAC cost for the amount given (Net Revenue Columns) for the 835 file provided with all Medicaid transactions for the period between 7-1-20 and 8-31-21

	HCPCS	Description	Net Revenue 340B	Net Revenue WAC •
1.	J9271	KEYTRUDA INJ 1MG	\$-370,571.31	\$-588,995.31
2.	J9303	PANITUMUMAB EA 10 MG	\$-215,633.98	\$-442,210.7
3.	J9299	NIVOLUMAB / OPDIVO, INJ 1MG	\$-122,496.18	\$-198,441.36
4.	J9035	BEVACIZUMAB 10 MG INJ HHI	\$12,504.57	\$-137,057.24
5.	J9022	TECENTRIQ/ATEZOLIZUMAB I	\$-52,826.64	\$-118,300.62
		Grand total	\$-724,187.56	\$-1,631,384.59
			1-24/24 < >	





Pharm D On Demand

a smarter pharmacy

706-389-9500

www.pharmdondemand.com